<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Ten anemic patients with favorable <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) were first treated with two 5-week courses of <z:chebi fb="0" ids="2636">amifostine</z:chebi> alone (each course consisted of 200 mg/m(2) of the drug given intravenously three times a week for 3 weeks), followed by an additional two courses combined with subcutaneous erythropoietin (EPO) (150 U/kg, three times a week for 8 weeks) </plain></SENT>
<SENT sid="1" pm="."><plain>The study patients either had previously failed to respond to treatment with EPO or had pretreatment serum EPO levels of more than 100 mU/ml </plain></SENT>
<SENT sid="2" pm="."><plain>None of the patients experienced a complete or partial response in <z:hpo ids='HP_0001903'>anemia</z:hpo> or other cytopenias </plain></SENT>
<SENT sid="3" pm="."><plain>We conclude that <z:chebi fb="0" ids="2636">amifostine</z:chebi> alone or in combination with EPO has limited therapeutic activity in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>